Specifically we combined comprehensive quantification of cancer rates in the US population (Surveillance and, Epidemiology and End Results, SEER data), with TP53 mutation rates in US cancers (as identified in The Cancer Genome Atlas, TCGA data) (Haupt et al., 2019a). The gene discussed is TP53; the disease is cancer.